- Report
- November 2024
Japan, United States, ... Japan, United States, Europe, Global
From €4295EUR$4,500USD£3,598GBP
- Report
- November 2024
Japan, United States, ... Japan, United States, Europe
From €1432EUR$1,500USD£1,199GBP
- Report
- October 2024
Global
From €3340EUR$3,500USD£2,799GBP
- Report
- April 2022
Japan, United States, ... Japan, United States, Europe, Global
From €2625EUR$2,750USD£2,199GBP
- Report
- December 2021
Global
From €4629EUR$4,850USD£3,878GBP
- Report
- August 2024
Japan, United States, ... Japan, United States, Europe
From €3340EUR$3,500USD£2,799GBP
The Cryptosporidium Test market is a segment of the In Vitro Diagnostics (IVD) industry. It is used to detect the presence of Cryptosporidium, a protozoan parasite that can cause gastrointestinal illness. The test is used to diagnose cryptosporidiosis, a diarrheal disease caused by the parasite. The test is used in clinical settings, such as hospitals and laboratories, as well as in public health settings, such as water testing facilities.
The Cryptosporidium Test market is expected to grow due to increasing prevalence of the disease, rising awareness of the disease, and increasing demand for rapid and accurate diagnosis. The market is also driven by technological advancements in testing methods, such as molecular diagnostics and immunoassays.
Some companies in the Cryptosporidium Test market include Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., QIAGEN N.V., Abbott Laboratories, and DiaSorin S.p.A. Show Less Read more